Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) Is Associated with Poor Prognosis in Gastric Cancer

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Wang, Da ^a   Li, Tingting ^a   Ye, Gengtai ^a   Shen, Zhiyong ^a   Hu, Yanfeng ^a   Mou, Tingyu ^a   Yu, Jiang ^a   Li, Sihao ^a,b   Liu, Hao ^a   Li, Guoxin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b SCNU   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; STOMACH CARCINOGENESIS; STOMACH MUCOSA; UPREGULATION; WESTERN BLOTTING; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH; STOMACH NEOPLASMS;

ADULT; ADVANCED GLYCOSYLATION END PRODUCT-SPECIFIC RECEPTOR; AGED; BIOMARKERS, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; STOMACH; STOMACH NEOPLASMS;

EID: 84928923384     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0122697     Document Type: Article

References (26)

1. Alexiou P, Chatzopoulou M, Pegklidou K, Demopoulos VJ. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Current medicinal chemistry. 2010; 17(21):2232-52. Epub 2010/05/13. PMID: 20459381.
2. Schmidt AM, Yan SD, Yan SF, Stern DM. The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. The Journal of clinical investigation. 2001; 108(7):949-55. Epub 2001/10/03. doi: 10.1172/jci14002 PMID: 11581294; PubMed Central PMCID: PMCPMC200958.
3. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W, et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature. 2000; 405(6784):354-60. Epub 2000/06/01. doi: 10.1038/35012626 PMID: 10830965.
4. Kostova N, Zlateva S, Ugrinova I, Pasheva E. The expression of HMGB1 protein and its receptor RAGE in human malignant tumors. Molecular and cellular biochemistry. 2010; 337(1-2):251-8. Epub 2009/10/31. doi: 10.1007/s11010-009-0305-0 PMID: 19876719.
5. Ishiguro H, Nakaigawa N, Miyoshi Y, Fujinami K, Kubota Y, Uemura H. Receptor for advanced glycation end products (RAGE) and its ligand, amphoterin are overexpressed and associated with prostate cancer development. The Prostate. 2005; 64(1):92-100. Epub 2005/01/25. doi: 10.1002/pros.20219 PMID: 15666359.
6. Sasahira T, Akama Y, Fujii K, Kuniyasu H. Expression of receptor for advanced glycation end products and HMGB1/amphoterin in colorectal adenomas. Virchows Archiv: an international journal of pathology. 2005; 446(4):411-5. Epub 2005/03/25. doi: 10.1007/s00428-005-1210-x PMID: 15789216.
7. van Beijnum JR, Nowak-Sliwinska P, van den Boezem E, Hautvast P, Buurman WA, Griffioen AW. Tumor angiogenesis is enforced by autocrine regulation of high-mobility group box 1. Oncogene. 2013; 32(3):363-74. Epub 2012/03/07. doi: 10.1038/onc.2012.49 PMID: 22391561.
8. Sasahira T, Kirita T, Bhawal UK, Ikeda M, Nagasawa A, Yamamoto K, et al. The expression of receptor for advanced glycation end products is associated with angiogenesis in human oral squamous cell carcinoma. Virchows Archiv: an international journal of pathology. 2007; 450(3):287-95. Epub 2007/01/20. doi: 10.1007/s00428-006-0359-2 PMID: 17235565.
9. Sasahira T, Kirita T, Bhawal UK, Yamamoto K, Ohmori H, Fujii K, et al. Receptor for advanced glycation end products (RAGE) is important in the prediction of recurrence in human oral squamous cell carcinoma. Histopathology. 2007; 51(2):166-72. Epub 2007/06/27. doi: 10.1111/j.1365-2559.2007.02739.x PMID: 17593216.
10. Wang X, Cui E, Zeng H, Hua F, Wang B, Mao W, et al. RAGE genetic polymorphisms are associated with risk, chemotherapy response and prognosis in patients with advanced NSCLC. PloS one. 2012; 7 (10):e43734. Epub 2012/10/17. doi: 10.1371/journal.pone.0043734 PMID: 23071492; PubMed Central PMCID: PMCPMC3465300.
11. Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, et al. Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. The Journal of pathology. 2002; 196(2):163-70. doi: 10.1002/path.1031 PMID: 11793367.
12. Xu XC, Abuduhadeer X, Zhang WB, Li T, Gao H, Wang YH. Knockdown of RAGE inhibits growth and invasion of gastric cancer cells. European journal of histochemistry: EJH. 2013; 57(4):e36. doi: 10.4081/ejh.2013.e36 PMID: 24441189; PubMed Central PMCID: PMC3896038.
13. Gu H, Yang L, Sun Q, Zhou B, Tang N, Cong R, et al. Gly82Ser polymorphism of the receptor for advanced glycation end products is associated with an increased risk of gastric cancer in a Chinese population. Clinical cancer research: an official journal of the American Association for Cancer Research. 2008; 14(11):3627-32. doi: 10.1158/1078-0432.CCR-07-4808 PMID: 18519797.
14. Liu D, Zhang L, Shen Z, Tan F, Hu Y, Yu J, et al. Increased levels of SLP-2 correlate with poor prognosis in gastric cancer. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2013; 16(4):498-504. doi: 10.1007/s10120-013-0232-3 PMID: 23371255.
15. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61(2):69-90. Epub 2011/02/08. doi: 10.3322/caac.20107 PMID: 21296855.
16. Jiao L, Taylor PR, Weinstein SJ, Graubard BI, Virtamo J, Albanes D, et al. Advanced glycation end products, soluble receptor for advanced glycation end products, and risk of colorectal cancer. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2011; 20(7):1430-8. doi: 10.1158/1055-9965.EPI-11-0066 PMID: 21527578; PubMed Central PMCID: PMC3132292.
17. Ito R, Ishii Y, Wakiyama S, Shiba H, Fujioka S, Misawa T, et al. Prognostic significance of receptor for advanced glycation end products expression in hepatocellular carcinoma after hepatectomy. The Journal of surgical research. 2014. Epub 2014/07/22. doi: 10.1016/j.jss.2014.06.028 PMID: 25043528.
18. Heijmans J, Buller NV, Hoff E, Dihal AA, van der Poll T, van Zoelen MA, et al. Rage signalling promotes intestinal tumourigenesis. Oncogene. 2013; 32(9):1202-6. Epub 2012/04/04. doi: 10.1038/onc.2012.119 PMID: 22469986.
19. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P, et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell death and differentiation. 2010; 17(4):666-76. Epub 2009/10/17. doi: 10.1038/cdd.2009.149 PMID: 19834494; PubMed Central PMCID: PMCPMC3417122.
20. Radia AM, Yaser AM, Ma X, Zhang J, Yang C, Dong Q, et al. Specific siRNA Targeting Receptor for Advanced Glycation End Products (RAGE) Decreases Proliferation in Human Breast Cancer Cell Lines. International journal of molecular sciences. 2013; 14(4):7959-78. Epub 2013/04/13. doi: 10.3390/ijms14047959 PMID: 23579957; PubMed Central PMCID: PMCPMC3645726.
21. Elangovan I, Thirugnanam S, Chen A, Zheng G, Bosland MC, Kajdacsy-Balla A, et al. Targeting receptor for advanced glycation end products (RAGE) expression induces apoptosis and inhibits prostate tumor growth. Biochemical and biophysical research communications. 2012; 417(4):1133-8. Epub 2011/12/31. doi: 10.1016/j.bbrc.2011.12.060 PMID: 22206663.
22. Liang H, Zhong Y, Zhou S, Peng L. Knockdown of RAGE expression inhibits colorectal cancer cell invasion and suppresses angiogenesis in vitro and in vivo. Cancer letters. 2011; 313(1):91-8. Epub 2011/09/29. doi: 10.1016/j.canlet.2011.08.028 PMID: 21945853.
23. DiNorcia J, Lee MK, Moroziewicz DN, Winner M, Suman P, Bao F, et al. RAGE gene deletion inhibits the development and progression of ductal neoplasia and prolongs survival in a murine model of pancreatic cancer. Journal of gastrointestinal surgery: official journal of the Society for Surgery of the Alimentary Tract. 2012; 16(1):104-12; discussion 12. Epub 2011/11/05. doi: 10.1007/s11605-011-1754-9 PMID: 22052106; PubMed Central PMCID: PMCPMC4049447.
24. Arumugam T, Ramachandran V, Gomez SB, Schmidt AM, Logsdon CD. S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(16):4356-64. Epub 2012/06/22. doi: 10.1158/1078-0432.ccr-12-0221 PMID: 22718861; PubMed Central PMCID: PMCPMC3845828.
25. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology. 2004; 39(2):422-32. Epub 2004/02/10. doi: 10.1002/hep.20045 PMID: 14767995.
26. Moy KA, Jiao L, Freedman ND, Weinstein SJ, Sinha R, Virtamo J, et al. Soluble receptor for advanced glycation end products and risk of liver cancer. Hepatology. 2013; 57(6):2338-45. doi: 10.1002/hep.26264 PMID: 23325627; PubMed Central PMCID: PMC3644530.